Salmonella vaccination in pigs: a review by Wales, Andrew & Davies, RH
1 
Salmonella vaccination in pigs: a review 
 
A. D. Wales* and R. H. Davies 
 
Department of Bacteriology and Food Safety,  Animal and Plant Health Agency Weybridge, Woodham Lane, 
New Haw, Addlestone, Surrey KT15 3NB, UK. 
 
 
 
*Author for correspondence 
Email: research@andy.wales 
Tel: +442920 842402 
 
 
 
Key words: Salmonella spp, swine, zoonoses, foodborne pathogens, preventive medicine 
 
2 
Abstract 
The control of Salmonella enterica in pig production is necessary for both public and animal health. 
The persistent and frequently asymptomatic nature of porcine Salmonella infection and the 
organism’s abilities to colonise other animal species and to survive in the environment mean that 
effective control generally requires multiple measures. Vaccination is one such measure, and the 
present review considers its role and its future, drawing on studies in pigs from the 1950s to the 
present day. Once established in the body as an intracellular infectious agent, Salmonella can evade 
humoral immunity, which goes some way to explaining the often disappointing performance of 
inactivated Salmonella vaccines. More recent approaches, using mucosal presentation of antigens, 
live vaccines and adjuvants to enhance cell-mediated immunity, have met with more success. 
Vaccination strategies that involve stimulating both passive immunity from the dam plus active 
immunity in offspring appear to be most efficacious, although either approach alone can yield 
significant control of Salmonella.  Problems that remain include relatively poor control of Salmonella 
serovars that are dissimilar to the vaccine antigen mix, and difficulties in measuring and predicting 
the performance of candidate vaccines in ways that are highly relevant to their likely use in 
commercial production. 
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The challenge for Salmonella vaccination in pig production 
Salmonella infection of commercially-produced pigs has been an ongoing issue for the industry for 
many years (Josland, 1954; McKinley et al., 1980; O’Brien, 1966), with public health protection 
becoming an increasingly dominant concern (Ojha and Kostrzynska, 2007). Source attribution studies 
for the European Union implicate poultry and pig meat as the commonest sources, after eggs, for 
human salmonellosis (EFSA, 2008). Salmonella serovars Typhimurium and Derby are commonly 
isolated from pig production worldwide, whereas the host-adapted Salmonella Choleraesuis is now 
rarely reported in Europe and Australia but is still frequently found in North America and Asia (Boyen 
et al., 2008; Gray et al., 1995). National prevalence values for Salmonella of between zero and 29% 
of pigs were reported from a recent systematic survey of ileo-caecal lymph nodes at slaughter in the 
European Union (EFSA, 2008). Other surveys of production herds in Asia, North America and Africa 
indicate, similarly, that carriage of Salmonella is common and typically not associated with clinical 
disease (Amaechi and Ezeronye, 2006; Eblen et al., 2005; Kim et al., 2010; Kishima et al., 2008; 
Rajic et al., 2005). Shifting patterns of Salmonella types have included the recent emergence on pig 
farms of monophasic DT193 and U302 strains closely related to Salmonella Typhimurium (EFSA 
Panel on Biological Hazards (BIOHAZ), 2010). 
 
Whilst many pig production facilities practise high standards of biosecurity and segregation, a 
particular feature of Salmonella within the modern, integrated industry is its persistent presence 
within the breeding pyramid (EFSA, 2009; Letellier et al., 1999; Wales et al., 2013). This ensures that 
production facilities are continually at risk of importing Salmonella with new and replacement 
breeding stock. Whilst it is possible to achieve a ‘clean break’ at weaning from Salmonella in the 
breeding herd, this is difficult to achieve consistently in practice as new waves of different strains 
pass though the herd, undermining the ‘herd-immunity’ effect that limits transmission of Salmonella 
from lactating sows to young sucking piglets (Wales et al., 2011). Attempts to eliminate Salmonella 
from pig units also have to contend with the organism’s resistance to removal from accommodation 
by conventional cleaning and disinfection methods (Funk et al., 2001; McLaren et al., 2011), and its 
frequent carriage on fomites and by wildlife (Barber et al., 2002; Berends et al., 1996). This means 
that the environmental persistence of Salmonella strains between batches of animals is very common, 
and may be the usual short-term determinant of the pattern of strains on a unit (Davies et al., 1998). 
 
Salmonella vaccination may be used with the intention of controlling clinical disease, or to reduce 
subclinical shedding. Historically in Europe, and in the present-day in some parts of the world, it may 
be necessary to attempt control of outbreaks of clinical disease associated with a particular strain, 
commonly of the host-adapted S. Choleraesuis. In such a situation, the use of an autogenous killed 
vaccine prepared from the outbreak strain is a rapid intervention that may be effective, in concert with 
other control measures (Barrow and Methner, 2013; Roesler et al., 2006) if a licensed commercial 
vaccine is not available. By contrast, vaccination for Salmonella in modern pig production is usually 
employed to suppress shedding and to reduce infection pressure in the context of continuous herd 
infection, although a clinical enteritis problem amongst weaned pigs may in some cases provide the 
impetus to start vaccinating. Vaccination of commercial piglets to completely prevent Salmonella 
colonisation would require freedom from Salmonella amongst dams and in early age accommodation. 
This is currently not a realistic scenario, and in this respect pig vaccination differs from Salmonella 
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vaccination of poultry, particularly in egg production where elite and layer-parent breeding flocks 
typically are unvaccinated and intensively monitored for Salmonella. In this situation Salmonella–
free layer and broiler parent poults are often protected by vaccination before possible exposure within 
accommodation (Davies and Wales, 2014). 
 
Attempting to protect the consumers of pig products by controlling sub-clinical carriage and shedding 
of Salmonella using vaccination presents a substantially different challenge compared with 
vaccination for disease control. Firstly, there will be a variety of strains (and often serovars) which 
ideally should be controlled. These will often belong to differing antigenic groups and therefore issues 
of cross-protection may arise. Secondly, the desired effect will be a reduction of tissue colonisation 
and/or shedding by the time of slaughter, as opposed to protection from morbidity and mortality. This 
will likely involve stimulating effective immunity against broad-host-range serovars such as 
S. Typhimurium, which show a different pattern of invasion, multiplication and dissemination 
compared with host-adapted S. Choleraesuis (Boyen et al., 2008). Thirdly, any vaccine should not 
have any adverse effect on serological monitoring for Salmonella infection, where this is employed 
before or at the time of slaughter. 
 
Measurement of the efficacy of any Salmonella vaccine in pigs needs to take account of the foregoing 
considerations about the intended use and required outcomes. For candidate vaccines to combat 
subclinical tissue invasion and shedding but without consequences for serological monitoring, it is 
necessary to decide on what constitutes a suitable study population, a natural versus an experimental 
challenge, and when and what to measure: morbidity, shedding, tissue invasion and/or load, plus 
serological responses (Denagamage et al., 2007). 
 
Salmonella vaccination: general considerations 
Salmonella is a pathogen that invades the body through mucosal surfaces, and which is facultatively 
intracellular, exhibiting both intracellular and extracellular phases of its colonisation of tissues. 
Infection via the alimentary tract involves transit through enterocytes into the lamina propria of the 
gut, followed by entry into macrophages and subsequent dissemination to other tissues by a 
combination of cell migration and repeated cycles of cell death, release of Salmonella and re-uptake 
by phagocytes (Haesebrouck et al., 2004; Mittrücker and Kaufmann, 2000). Details of the degree and 
modes of tissue invasion appear to differ between host-adapted and broad-host-range serovars, and 
between host species (Boyen et al., 2008). 
 
Humoral immunity to Salmonella infections has limited effect (O’Brien, 1966), because for much of 
the infection cycle the organism is within body cells, shielded from antibody action. Nonetheless (and 
unusually for cell-invasive bacteria) there is a strong humoral response to natural infection, including 
secretory IgA responses that may be effective in preventing initial invasion of the mucosa (McSorley 
and Jenkins, 2000; Mittrücker and Kaufmann, 2000). Cell-mediated immunity (CMI), characterised 
by a T-helper1 (Th1) lymphokine profile associated with activation of macrophages and cytotoxic 
lymphocytes, appears to be a critical part of effective anti-Salmonella immunity (Lindberg and 
Robertsson, 1983; Murtaugh, 2014). 
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Live Salmonella vaccines, presented to mucosal surfaces, theoretically offer the best combination of 
antigen presentation and co-stimulatory signals to elicit CMI and mucosal immunity (Haesebrouck et 
al., 2004). Indeed, such are its immunogenic properties and targeting to the mucosal immuno-
inductive Peyers patch sites that Salmonella has been genetically manipulated and used as an 
experimental vehicle for presenting viral, parasitic and other bacterial antigens, (Hur et al., 2012; Kim 
et al., 2012; Xu et al., 2012). Live attenuated Salmonella strains offer the additional advantage for  
pigs that inoculation can be performed by non-parenteral routes (principally in drinking water or by 
aerosol), without the need for handling and injection of individual animals. 
 
However, effective mass vaccination with live vaccines can be technically demanding to accomplish 
reliably as there are many potential obstacles to achieving administration of a sufficient dose to all 
individuals. Live vaccines may readily be degraded or inactivated by inappropriate storage or 
reconstitution, or by interfering substances such as other micro-organisms or sanitisers in water 
supplies. Water lines of varying length, blocked or damaged drinkers, and individual animals’ varied 
behaviours in respect of social hierarchy and drinking can all militate against a predictable 
distribution and uptake of vaccine in drinking water (Vermeulen et al., 2002). Such issues have led to 
attempts to incorporate vaccine with liquid feed rather than water (Edmonds et al., 2001). 
 
There has also been a substantial effort over the years in developing killed Salmonella vaccines. This 
was a matter of utility and necessity in earlier decades when genetic attenuation techniques were in 
their infancy and Salmonella vaccination was largely a matter of controlling clinical disease 
associated with host-adapted serovars, particularly Salmonella Choleraesuis in pigs. More recently, 
killed vaccines have regained some appeal in view of their safety profile for consumers, predictable 
if labour-intensive dosing, and zero risk of reversion to virulence. This last issue is a potential hazard 
with live vaccine strains that, by mutation or acquisition of genetic material in the field, might re-
acquire virulent characteristics. Whilst experience with other licensed live vaccines, including 
Salmonella vaccines in poultry, has been reassuring in this respect, the development, testing and 
licensing of live vaccine strains is consequently more onerous than for non-living vaccines. 
Furthermore, advances in adjuvant technology and appreciation of the importance of growth 
conditions on suitable antigen expression has improved the effect, including on CMI, by killed 
vaccines (Barrow and Methner, 2013). 
 
Technical aspects of candidate vaccine development 
There are a number of strategies that may be used when trialling or implementing vaccination of pigs 
against Salmonella, and assessment of the vaccine protection needs ultimately to take account of its 
likely mode of use in the field. The age and production stages at which vaccination potentially can be 
used includes pre-weaning, weaner and grower stages for commercial rearing, pre-farrowing for 
generating passive immunity in piglets of farrow-to-finish herds, or regular vaccination of adults in 
breeding herds. 
 
The dose, route and frequency of administration will depend on the nature of the candidate vaccine, 
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but is often the subject of a certain amount of trial and error. In theory, live vaccine strains should 
generate a strong immune response after one dose if they colonise and invade tissues to which they 
are applied. However, there is often a fine balance between sufficient attenuation and sufficient 
stimulation, and this may vary between serovars (Barrow and Methner, 2013; Coe and Wood, 1992; 
Kennedy et al., 1999; Linde et al., 1990). It cannot therefore be assumed that a single dose of a live 
strain will be sufficient. Killed vaccines are generally given by injection in two doses with adjuvant. 
 
There are many approaches to the generation of candidate live vaccine strains by attenuation. Several 
defined-deletion mutants have been reported in the context of pig vaccination, as reviewed by Chu 
(2007) and Haesebrouck (2004). These include metabolic mutants with deletions affecting the 
aroACD aromatic amino acid synthesis or purABEH purine synthesis operons, the galE galactose-
glucose metabolism gene, or the global regulator genes cya (adenylate cyclase) and crp (cAMP 
receptor protein). Deletion of the virulence plasmid spv genes following repeated passage through 
neutrophils has been reported (Kramer et al., 1992). Other mutations affecting survival in the body or 
invasiveness include cpxR (regulation of envelope stress response plus pili and fimbria) and lon 
(regulator of Salmonella pathogenicity island 1, affecting replication and survival within 
macrophages) (Hur et al., 2011; Hur and Lee, 2010), also znuABC zinc transporter operon (Pesciaroli 
et al., 2013). Other approaches to generating more or less well-defined attenuations include 'metabolic 
drift' mutations, with reduced growth rates linked to antibiotic resistance (Roesler et al., 2004), and 
auxotrophic strains generated by chemical mutagenesis that have specific growth requirements. The 
latter include the two 'Salmoporc’ commercial vaccine strains that are unable to synthesize adenine. 
These also have additional attenuation, in the form of histidine auxotrophy or a stable rough 
phenotype for the ‘STM’ Typhimurium and ‘SCS’ Choleraesuis strains, respectively (Schöll and 
Grünert, 1980; Springer et al., 2001). 
 
Under-attenuation can result in unacceptable clinical signs following administration, whilst over-
attenuation leads to inadequate immune stimulation associated with poor in vivo survival, 
colonisation, or antigen expression by the vaccine strain. There are serovar differences in the effects 
of certain attenuations. As might be expected, genetic disruptions aimed at surface antigens can yield 
strains with greatly varying immunogenic effects (Leyman et al., 2011). Disrupting cpxR, which 
encodes a regulator of fimbria amongst other things, may increase antigen expression and 
immunogenicity (Hur and Lee, 2010). Attenuation may affect survival and growth of Salmonella in 
the environment too (Linde et al., 1990), which may be helpful in ensuring the absence of the vaccine 
strain by the time of slaughter. 
 
Additional techniques trialled with live vaccines have included using Escherichia coli labile 
enterotoxin to act as an adjuvant for mucosal immunity (Hur et al., 2011), and using mixtures of live 
vaccine strains to address cross-protection against more than one serogroup. However, the latter 
approach has run into problems of interference between strains, causing reduced immunogenic effect 
(Barrow and Methner, 2013). 
 
Attempts to use killed Salmonella vaccines to control clinical disease, either experimentally or in the 
face of natural infection, have met with mixed success (Arguello et al., 2013; Gradassi et al., 2013; 
Josland, 1954; Roesler et al., 2006). There are probably several factors that have influenced outcomes 
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in these studies, including variations in vaccination protocols (dose, frequency and route), 
preparations (growth conditions, inactivation method, adjuvant) and strains, both vaccine and 
challenge. A strong mucosal IgA response may be a significant element of vaccine protection against 
both colonisation and clinical disease (Roesler et al., 2004). 
 
Traditional adjuvants use vehicles such as oil, emulsions or aluminium salts to immobilise antigens 
and enhance their presentation in tissues. Immuno-modulating adjuvants additionally, or alternatively, 
provide co-stimulatory signals to enhance the response in terms of type (Th1/CMI versus 
Th2/humoral) and intensity. In the long-established case of Freunds complete adjuvant this is 
achieved via the inclusion of killed mycobacterial material (Stills, 2005). Modern developments in 
respect of Salmonella vaccine adjuvants have attempted to enhance the Th1-type response, to lessen 
tissue reactions, and to provide adjuvant activity for orally-administered vaccines. Much work has 
yet to be translated from laboratory animals to livestock. 
 
Co-stimulatory signalling of antigen-presenting cells occurs after activation of innate immunity 
through recognition of pathogen-associated molecular patterns by sensors such as Toll-like receptors 
(TLR). This can overcome mucosal tolerance of antigens on killed or subunit vaccines given orally 
(Rueckert and Guzman, 2012; Salman et al., 2009). The conserved domains of bacterial flagellin 
subunits (FliC and FljB) are ligands for TLR5 receptors, and are associated in mice with enhancement 
of an immune response to antigens presented as a fusion protein with flagellin (Huleatt et al., 2007; 
Qian et al., 2015; Yang et al., 2013), or as a separate molecule (Girard et al., 2011). The route of 
administration (oral, respiratory mucosal, injection) appears to affect the Th1/Th2 bias and mucosal 
(IgA) response obtained. Salmonella engineered to over-express flagellin showed increased 
immunogenicity in mice, as well as increased susceptibility to killing by phagocytes (Yang et al., 
2012). 
 
Other potential adjuvants for Salmonella vaccines include E. coli labile enterotoxin and Cholera 
toxin, which have immunomodulatory adjuvant effects in the gut probably associated with the 
promotion of antigen uptake and immune cell stimulation (Freytag and Clements, 2005). Efforts to 
circumvent the enterotoxic effects associated with labile enterotoxin have revealed adjuvant activity 
of the non-enterotoxic B subunit when engineered into a live Salmonella Gallinarum vaccine for 
poultry (Nandre and Lee, 2014), and also when administered trans-cutaneously (Fingerut et al., 2006; 
Tagliabue and Rappuoli, 2008). Although cholera toxin is well tolerated by pigs, compared with 
humans, its adjuvant effects on co-administered antigens appear to be modest compared with effects 
in mice, and rely substantially on close association between toxin and antigen (Foss and Murtaugh, 
1999). 
 
Polymer nanoparticles are another potential adjuvant, being taken up by antigen-presenting cells and 
showing an inherent capacity to stimulate some TLR classes (Tamayo et al., 2010). When antigen and 
co-stimulatory molecules (flagellin, mannosamine) were mounted on them, nanoparticles 
administered orally to mice promoted robust immune responses, shifted towards the Th1 pattern and 
mucosal IgA (Salman et al., 2009). 
 
A specific issue with Salmonella vaccines for endemic, subclinical colonisation by broad-host-range 
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serovars is distinguishing immunological responses generated by vaccination from those due to 
ongoing cycles of infection. If vaccination is performed at an early age and is effective at reducing 
and preventing natural infection, this may not be a major issue as serological responses may be 
minimal by slaughter age, and indeed reduced compared with non-vaccinated groups if effective 
Salmonella control is achieved (Foss et al., 2013; Husa et al., 2009). However, if Salmonella is still 
circulating, vaccination can act as a ‘priming’ dose and result in a greater antibody response to the 
field infection.  When it is necessary to show complete freedom from Salmonella infection, for 
example in breeding herds, then so-called DIVA (Differentiating Infected from Vaccinated Animals) 
vaccines are useful tools. These vaccines generally will lack specific antigens or epitopes (Leyman 
et al., 2011; Selke et al., 2007), and a serological test can be used to discriminate vaccine from natural 
infection. 
 
Experimental studies 
Vaccination of dams and/or pre-weaned piglets. There are a few studies, summarised by Wales et 
al. (2011), examining the protective effect on neonates and weaners of maternal vaccination aimed at 
providing passive immune protection against colonisation. Chu et al. (2007) reported increased and 
prolonged antibody in the serum of piglets born to dams given an experimental live attenuated 
S. Choleraesuis vaccine. A commercial live S. Choleraesuis rough mutant vaccine (“Suscovax”; 
Smith, 1965) was given parenterally to two sows at three and one weeks antepartum (Hanna et al., 
1979a). It was associated in offspring with detectable somatic and flagellar antibodies and with partial 
protection against clinical signs and tissue colonisation by the same serovar, given as a challenge 
intranasal dose. A killed autologous vaccine of S. Typhimurium DT104 appeared to provide 
substantial protection when given in an intensive (oral plus parenteral) protocol to sows whose litters 
were subject to natural challenge (Roesler et al., 2006). Offspring of vaccinated sows had lower 
S. Typhimurium IgG and IgA titres than controls when examined at 16 to 20 weeks (suggesting less 
exposure to Salmonella after the waning of passive immunity) and zero isolations of Salmonella up 
to 142 days, with controls frequently yielding S. Typhimurium on culture. Results from a small study 
by Matiasovic et al. (2013) concur; a S. Typhimurium DT104 killed vaccine given in two doses ante-
partum was associated with reduced mucosal and tissue colonisation of piglets four days after dosing 
at three days of age with the vaccine strain. 
 
Hur and Lee (2010) dosed pregnant sows orally with a defined attenuated S. Typhimurium strain 
(Δlon, ΔcpxR) together with a derived strain producing labile enterotoxin. Offspring of vaccinated 
sows showed reduced clinical signs and Salmonella shedding when challenged with the virulent 
parent strain at one week of age. The two-dose trial administration protocols included parenteral killed 
and oral live doses, but only those where the second dose was oral live were associated with 
protection. Experiments using these same vaccines and sow protocols, plus vaccination of offspring 
at two weeks of age (parenteral, killed) and five weeks of age (live, oral) were reported by Hur et al. 
(2011). Humoral immunity was increased in piglets born to immunised sows, as assessed by IgG 
titres, but only piglets which themselves had been vaccinated were significantly protected from 
virulent challenge by S. Typhimurium at 11 weeks of age. Complete protection was only seen 
following vaccination of both sows and their piglets. 
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Eddicks et al. (2009) examined responses to oral administration of the 'Salmoporc STM' commercial 
double-auxotrophic S. Typhimurium strain at three and 21 days of age. By four weeks of age, 
seroconversion was noted and shedding of the vaccine strain had ceased, although it was found in 
tissues at up to six weeks of age. Further work on vaccination of both dams and young piglets with 
this vaccine was reported in a small study (nine sows, 58 piglets) by Roesler (2010). Oral vaccination 
of piglets at three days of age and at weaning (28 days) was followed by transient invasion of body 
tissues and shedding of the vaccine strain, without clinical signs. There was significant protection 
among vaccinates against clinical signs, shedding and tissue invasion following a challenge dose of 
S. Typhimurium DT104 at seven weeks of age. Interestingly, parenteral antepartum vaccination of 
the dams was associated with reduced tissue invasion of the vaccine strain in piglets, but this did not 
result in reduced protection against the post-weaning challenge dose. Indeed, excretion of the virulent 
DT104 strain was lowest among these piglets. Serological analysis suggested that neither vaccination 
of dams nor piglets would compromise serological monitoring at slaughter age. The authors suggested 
that, whilst active immunity was needed for protection of weaners and older pigs, humoral immunity 
in the gut and tissues provided by maternal vaccination should protect against early infection and 
reduce Salmonella challenge among young piglets. 
 
Vaccination starting around the time of weaning. Several studies have examined vaccination of 
piglets within the one- to two-month age range. The immune cell population in the intestine of piglets 
resembles that of the adult by about seven weeks of age, although some subsets of cells (for example 
CD4+ lymphocytes) appear to be well-established sooner than this (Stokes et al., 2004; Vega-López 
et al., 1995). 
 
Josland (1954) reported modest and variable clinical protection of weaners using formalin- or 
ultraviolet-inactivated S. Choleraesuis (three weekly doses) against heavy same-serovar challenge in 
small-scale trials. Lawson and Dow (1965) demonstrated protection afforded by an attenuated (rough) 
strain of S. Choleraesuis given parenterally at three to five weeks of age, against clinical signs and 
shedding following a challenge oral dose of the same serovar around 12 days later. Similarly, Smith 
(1965) reported marked reductions in clinical signs, mortality and enteric lesions among pigs injected 
with either of two rough mutant S. Choleraesuis strains at eight weeks of age, then challenged with 
the parent strain three weeks later. 
 
Hanna et al. (1979b) examined the efficacy of a rough attenuated commercial S. Choleraesuis vaccine 
(Suscovax) derived from one of the above strains used by Smith (1965). There was reduced mortality 
and shortened phases of bacteraemia and nasal carriage following intranasal S. Choleraesuis 
challenge two weeks after Suscovax was given subcutaneously to seven-week-old weaners. Another 
undefined attenuated S. Choleraesuis strain was used by Kramer et al. (1987), given by injection or 
into the conjunctival sac of weaners followed by same-serovar challenge four weeks later. Significant 
reductions in clinical signs and systemic lesions were observed in vaccinated individuals over the 
following month, and there was a delayed cutaneous hypersensitivity to S. Choleraesuis outer 
membrane protein extract (consistent with a specific cell-mediated immune response) following 
vaccination. 
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A strain (SC-54) of S. Choleraesuis that had been attenuated by repeated passage through porcine 
neutrophils resulting in (amongst other things) loss of the virulence plasmid has been used in studies 
with young pigs. Roof and Doitchinoff (1995) administered it intra-nasally to four-week-old pigs and, 
following S. Choleraesuis challenge by the same route up to 20 weeks later, clinical signs were absent 
and tissue invasion was reduced in vaccinates compared with controls. Field studies by Kramer et al. 
(1992) confirmed the strain's efficacy against field challenge by S. Choleraesuis when administered 
into the nasopharynx of nursery pigs. This strain is at present commercially marketed in some 
territories, as 'Enterisol SC-54'. 
 
Oral administration of a metabolic drift mutant of S. Typhimurium with mutations in gyrA, cpxA and 
rpoB to four-week-old weaners was followed by limited tissue invasion and a brief period of shedding 
but no clinical signs (Roesler et al., 2004). Vaccinated animals were relatively protected against 
clinical disease, shedding and tissue invasion following challenge with virulent S. Typhimurium 
DT104 three weeks later. Interestingly, vaccinates mounted a stronger IgA response to challenge than 
did unvaccinated animals, whose IgG responses were comparatively more intense. 
 
In recent years, trials have often used vaccine candidates with defined attenuations. A double-
attenuated (plasmid-cured, crp mutant) strain of S. Choleraesuis was given as a single oral dose to 
five-week-old weaners followed by a severe challenge with an unrelated field strain of 
S. Choleraesuis one to two weeks later (Chu et al., 2007). Mortality and severe morbidity was seen 
in challenged control animals. Milder clinical signs and lessened tissue lesions were seen among 
vaccinates, as was evidence of specific CMI in a lymphocyte proliferation assay. Kennedy et al. 
(1999) examined the effects of various attenuating S. Choleraesuis mutations upon protection against 
lesions and clinical signs following challenge. Against a background of Δcya/Δcrp, loss of virulence 
plasmid or of muscle invasion capacity did not alter the vaccinial protection afforded, but attenuation 
of lipopolysaccharide synthesis did reduce protection. 
 
An aroA mutant of S. Typhimurium, given as a two-dose injection starting at five to six weeks of age, 
was associated with reduced frequency of shedding of the (low virulence) challenge strain but similar 
mild clinical signs were seen in both the test and the unvaccinated control animals (Lumsden et al., 
1991). In a related study using the same vaccine and challenge strains in similar-aged animals, post-
challenge humoral responses (measured by agglutination assays) were similar between vaccinated 
and control animals, but vaccinates showed evidence of more CMI, measured by a Salmonella O-
antigen-stimulated lymphocyte proliferation assay (Lumsden and Wilkie, 1992). Interestingly, despite 
litters being split and mixed, the source litter exerted a significant effect upon measured immune 
responses. Litter and sire effects upon CMI following ΔaroA S. Typhimurium vaccination were also 
seen in a follow-up study using the same assay (Lumsden et al., 1993). 
 
Coe and Wood (1992) gave a single oral dose of a cya/crp mutant of S. Typhimurium to colostrum-
deprived pigs around two months of age. Challenge with S. Typhimurium three weeks later was 
followed by serial post-mortem examinations. Animals only given the vaccine strain showed mild 
clinical signs (pyrexia and some soft stool) plus tissue invasion that was similar in extent and duration, 
but lower in intensity, than those given only the challenge strain. Animals vaccinated then challenged 
showed reduced severity of pyrexia and diarrhoea, plus a reduced duration of tissue invasion and 
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lower Salmonella counts in the ileum, than did controls. Therefore, efficacy as a vaccine was 
countered by limited attenuation in these highly-susceptible piglets. Similarly, Barrow et al. (2001) 
reported low attenuation of a S. Typhimurium cya/crp mutant (compared with an aroA mutant) for 
young colostrum-deprived piglets. 
 
The commercial S. Typhimurium vaccine 'Salmoporc STM' has been the subject of several reports. 
Springer et al. (2001) administered the vaccine either in two oral doses or an oral plus an 
intramuscular dose, with oral challenge by S. Typhimurium DT104 five to six weeks later. Clinical 
signs were inconsistent in control animals but were reduced in intensity and duration in vaccinates. 
At post-mortem examination up to 10 days post-challenge Salmonella counts in the ileum and caecum 
were significantly reduced, although counts in intestinal lymph nodes were inconsistently reduced 
compared with control animals. Antibody titres in vaccinated animals around six weeks after the 
second dose were, almost without exception, below the cut-off point of a Danish meat-juice 
monitoring ELISA. Another study, using Salmoporc STM at four and seven weeks of age followed 
by S. Typhimurium challenge two weeks later, examined effects of a glucocorticoid dose (mimicking 
stress immunomodulation) given three weeks post-challenge. Post mortem examination one day after 
dexamethasone was administered showed a significantly reduced extent and intensity of tissue 
colonisation among vaccinated pigs. Salmoporc STM was also given as a two-dose course to weaners 
in a comparative trial using a strain with an antigenically-modified outer membrane protein (OmpD), 
as a candidate DIVA vaccine (Selke et al., 2007). A week after challenge with the same serovar, pigs 
given either the original or the modified vaccine strains exhibited protection against clinical signs of 
salmonellosis and had significantly reduced tissue Salmonella loads. 
 
Two related studies have examined both transmission and susceptibility among vaccinated animals 
by using vaccinated seeder pigs to expose groups of young vaccinated pigs. Pigs were vaccinated 
orally at three and six weeks with Salmoporc STM (De Ridder et al., 2013a) or at four and seven 
weeks with Salmoporc STM modified by a deletion (ΔrfaJ) affecting lipopolysaccharide (LPS) 
synthesis (De Ridder et al., 2013b). Vaccinated seeder pigs were challenged two weeks later with 
S. Typhimurium and re-introduced into groups of vaccinates. Salmoporc vaccination was associated 
with significantly fewer pigs shedding the challenge strain than non-vaccinates, but the percentage of 
colonised tissues five weeks after challenge was not significantly different from untreated control 
animals. Use of the ΔrfaJ Salmoporc vaccine strain was associated with a significant reduction in the 
proportion of Salmonella-positive tissues six weeks after challenge, but only when it was used in 
conjunction with coated butyric acid in feed. This candidate DIVA vaccine strain additionally did 
permit discrimination between vaccinated and infected animals using a standard monitoring ELISA 
targeted at LPS antigens. 
 
Several reports have discussed cross-protection following weaner-age pig vaccination. In a small 
study by Groninga (2000) a commercial live double-attenuated S. Choleraesuis vaccine was 
administered parenterally at three weeks of age, and pigs were challenged intra-nasally by a dissimilar 
serogroup (Salmonella Derby) two weeks later. Vaccination was associated with a significant (partial) 
reduction in tissue loads at post mortem examination between two and six weeks post-challenge. 
Charles et al. (2000) reported trials with a commercial S. Choleraesuis Δcya Δcrp vaccine (Argus SC) 
given to weaners in drinking water, who were subsequently challenged with S. Typhimurium. At a 
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higher challenge dose (1010 cfu/pig), clinical signs were ameliorated in vaccinated animals but 
shedding and tissue colonisation by the challenge strain was similar to controls. When the challenge 
dose was lower (106 cfu/pig), tissue colonisation was less frequent and extensive, and shedding was 
less prolonged and less intensive in vaccinated animals. 
 
Cross-protection was also examined by Husa et al. (2009), who reported that two live attenuated 
S. Choleraesuis commercial vaccines (Enterisol SC-54 and Argus SC/ST, both previously discussed) 
administered orally to month-old pigs were associated with reduction of clinical signs following intra-
nasal challenge with S. Typhimurium six weeks later. Qualitative isolations from tissues post mortem 
did not differ significantly from controls. One further study (Foss et al., 2013) used three-week-old 
pigs given attenuated (Δcya Δcrp) mutants of either S. Typhimurium or S. Choleraesuis orally, and 
then challenged three weeks later with a non-attenuated Salmonella. The challenge strains, variously, 
were one of: the same serovar, the same serogroup, or a different serogroup from the vaccine strain. 
Reductions in challenge strain shedding and tissue colonisation at post mortem examination four 
weeks later were seen with both vaccines, but the degree of protection lessened as the antigenic 
similarity between vaccine and challenge strains diverged, despite measures of humoral and cell-
mediated responses to challenge appearing similar. 
 
Vaccination of older growing pigs. A S. Typhimurium bacterin given orally in two doses did not 
protect fattening pigs against clinical signs or tissue invasion by experimental same-serovar 
challenge, although shedding was reduced (Gradassi et al., 2013). A novel recent approach to 
attenuation has involved mutating the zinc transport operon (znuABC) in S. Typhimurium, to produce 
a non-persistent strain that provokes mild pyrexia only, when administered to three-month-old pigs 
(Pesciaroli et al., 2013). Such a strain should provoke, but not survive, an inflammatory response. Its 
one-dose administration to three- to five-month-old pigs was associated with significant reductions 
in clinical signs, shedding and tissue invasion following virulent S. Typhimurium challenge (Gradassi 
et al., 2013). 
 
Field studies 
Salmonella vaccination studies involving natural challenge in field situations are far less common 
than small-scale single-dose challenge studies with short-term endpoints. An early field trial (Josland, 
1954) failed to demonstrate any clinical protection associated with inactivated S. Choleraesuis (109 
cfu with alum adjuvant) given to weaners. The challenging serovar(s) were undefined and the vaccine 
was given as a single injection. Palyusik (1964) injected a formalin-inactivated S. Typhisuis vaccine 
to dams and weaned pigs (single dose) plus unweaned piglets (two doses) in a field trial of over 5000 
animals in units where swine paratyphoid disease was established. Substantial but partial protection 
against clinical disease and mortality was observed. 
 
Arguello et al. (2013) conducted a field trial using an inactivated S. Typhimurium DT104 vaccine 
(1010 cfu, adjuvanted with aluminium hydroxide) injected into grower pigs at around 10 and 13 weeks. 
For S. Typhimurium, there were significant reductions in shedding after vaccination and in 
colonisation of mesenteric lymph nodes and caecum at slaughter, although Salmonella of other 
13 
serogroups was not significantly reduced. A recent trial of an autologous monophasic S. Typhimurium 
vaccine, also inactivated and adjuvanted with aluminium hydroxide, used a subset of sows and piglets 
on a multisite farrow-to-finish unit, with mixing of vaccinated and unvaccinated pigs at the post-
weaning stage (Ruggeri et al., 2015). Immunisation of sows ante-partum plus piglets (at four and 
eight weeks) provided the most consistent reductions in shedding and tissue contamination at 
slaughter. Some protection was seen where immunisation was performed at only one life stage, but 
results were more variable and lacked statistical significance. 
 
Rough mutant S. Choleraesuis strains were given by injection to eight-week-old weaners on a farm 
with endemic S. Choleraesuis disease (Smith, 1965). Post-weaning mortality was more than halved 
in vaccinated versus control groups, whilst evidence of systemic S. Choleraesuis infection was seen 
in around four times as many control as vaccinated animals. A trial covering eight farms (12,000 pigs) 
with endemic S. Choleraesuis infection, using the Enterisol SC-54 attenuated S. Choleraesuis strain 
administered at around 109 cfu per individual in drinking water, was reported by Kramer et al. (1992). 
Clinical cases were not seen after vaccination was started, and a clinical outbreak on one unit was 
halted rapidly. The same SC-54 (C1 serogroup) vaccine strain was trialled in a field study dosing 
piglets once, on the first day after birth in a breeding/finishing integration with predominantly B-
serogroup endemic strains (Schwarz et al., 2011). At slaughter, individual-level seroprevalence and 
mesenteric lymph node colonisation among test animals (45% and 33%, respectively) were modestly 
but significantly decreased compared with control animals (80% and 60%, respectively). 
 
A further trial used another commercial S. Choleraesuis vaccine (Argus SC/ST; Δcya Δcrp) given in 
drinking water at three and 16 weeks of age to pigs on a unit with diverse endemic Salmonella 
serovars (Maes et al., 2001). Compared with unvaccinated controls, there were significantly fewer 
(0.6% vs, 7.2%) Salmonella-positive ileo-caecal lymph nodes among animals at slaughter. However, 
seroprevalence near slaughter age was higher than, or similar to, control animals depending on 
whether the ELISA was interpreted with a higher or a lower sensitivity, respectively, using optical 
density cut-off values of >10% versus >40% of positive control. 
 
Summary and conclusions 
Salmonella vaccination in pigs has to contend with an antigenically-diverse pathogen that, once 
within tissues, can largely evade antibody-mediated attack. Evidence from experimental challenge 
studies indicates that CMI and secretory (IgA) humoral responses to vaccination are important in 
providing significant levels of protection against clinical and subclinical consequences of Salmonella 
exposure. However, strong mucosal immunity provided by passive transfer of colostral 
immunoglobulin may be sufficient alone to prevent Salmonella colonisation of pre-weaned piglets. 
 
Most trial reports focus on vaccinating young pigs and use a single high-dose challenge followed by 
monitoring and sampling for days to a few weeks in order to assess vaccine effects. Many candidate 
vaccines have proven efficacious in terms of preventing or reducing clinical signs of salmonellosis 
associated with a serovar matched to the vaccine, and a large field trial involving units affected by 
S. Choleraesuis has borne this out. Reports of trial vaccines using serovars other than Choleraesuis or 
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Typhimurium are rare. 
 
There is, however, comparatively little information on the abilities of candidate vaccines to reduce or 
eliminate Salmonella carriage and shedding by the time of slaughter, which is when Salmonella in 
pig production may potentially lead to Salmonella contamination in pig products, resulting in human 
disease. Findings from a study where challenge doses were varied suggests that vaccination that 
protects against clinical signs but not tissue invasion, carriage and shedding after a high-dose 
Salmonella challenge, may in fact reduce tissue invasion and shedding when the challenge dose is 
lower. This is supported by another study where Salmonella was isolated least frequently from 
animals where vaccination and feed interventions were combined. Nonetheless, there remains a 
substantial gap in the data regarding outcomes that are significant for public health protection. Given 
the sub-clinical endemic nature of much Salmonella infection of pigs in modern production systems, 
the principal driver for the use of Salmonella vaccination is likely to be perceived benefits in herd 
Salmonella status at marketing. Widespread adoption of vaccination for this purpose will require 
better evidence than currently exists. 
 
Killed vaccines, with appropriate administration protocols and adjuvants, have shown protective 
effects against antigenically-similar strains in experimental challenge and field studies, and additional 
strategies (such as using enteric toxins or nanoparticles as adjuvants for orally-presented antigen) may 
extend the usefulness of this approach. Furthermore, some live vaccines have additionally been able 
to demonstrate a degree of cross-protection against differing Salmonella serogroups in both small-
scale challenge and field trials. On current evidence, lipopolysaccharide O-antigen appears to be of 
high importance in stimulating effective protection, and the degree of protection seen lessens as the 
somatic antigens of challenge strains diverge from those of the vaccine strains. Where autologous 
bacterins are to be used, careful sampling followed by analysis of multiple isolates may allow the 
selection of a strain (or strain mix) that includes surface antigens present on many or all of the 
prevalent serovars, according to published antigenic formulae (Grimont and Weill, 2007). However, 
the partial nature of protection afforded by candidate and licensed vaccines in all studies is consistent 
with the view that the elimination of Salmonella from production herds by vaccination alone is 
probably over-optimistic. 
 
Protection of very young piglets from Salmonella colonisation holds out the prospect of very 
substantial reductions, or complete elimination, of Salmonella load at the start of rearing. Despite the 
immaturity of the piglet immune system, present evidence indicates that a combined strategy of 
maternal vaccination followed by early vaccination of pre-weaned piglets is needed for best 
protection against challenge in the post-weaning period. Antibody titres from colostral passive 
immunity are minimal by around eight weeks of age (Wales et al., 2011). The identification of 
significant effects of litter and sire upon piglet vaccine protection (Lumsden et al., 1993; Lumsden 
and Wilkie, 1992) suggests that genetic and/or environmental factors may influence the outcome of 
vaccination programmes. 
 
There are a number of areas where innovation may make distinct contributions to advances in 
Salmonella vaccine creation and delivery. Mucosal delivery routes, such as intranasal spray (Braucher 
et al., 2012; Feng et al., 2013), can enhance cell mediated and local immune responses, and need to 
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be optimised for delivery in modern pig production systems.  There has been some success in 
producing efficacious experimental DIVA vaccines that may prove especially useful in high health 
status breeding herds, as relevant investigations have mostly indicated that the effects of non-DIVA 
vaccines upon current regimes of serological monitoring at slaughter may be neutral or beneficial. 
However, more stringent monitoring criteria associated, for example, with assurance schemes may 
make DIVA vaccines more attractive for production herds in the future. Other vaccine technologies 
that may prove useful, but which have not yet been reported in pig Salmonella studies, include ghost 
cell preparations (Szostak et al., 1996) and purified antigen subunit preparations. Salmonella is 
regarded as a promising vector for the delivery of DNA vaccines (Bartolomé et al., 2010; Ingolotti et 
al., 2010), which may therefore facilitate the development of vaccination against Salmonella itself 
via this technology. 
 
The core region of surface lipopolysaccharide is particularly conserved in S. enterica (Heinrichs et 
al., 1998), more so than for E. coli. This provides a possible avenue to address the challenge of 
inducing effective cross-protection against diverse serovars, as some rough mutants (with core 
regions and other outer membrane antigens exposed to immune receptors) have proved to be 
immunogenic and partially protective against heterologous serovar challenge in mice (Nagy et al., 
2008; Nnalue et al., 1999). Thus, strains with partial or conditional suppression of O-antigen might 
achieve both increased cross-reactivity and, if used as live vaccine, a suitable degree of attenuation. 
Another potential avenue for exploration is the use of rationally attenuated Salmonella that has been 
genetically engineered to express other antigens, as a vector organism for a multiplex live vaccine, as 
briefly discussed earlier. A potential problem with this is that exposure to field Salmonella infection 
may lead to an immune response that limits the uptake and response to subsequent vector vaccines. 
Nonetheless, this approach could address the problem of serovar cross-protection by involving 
diverse antigens from a range of Salmonella serovars, or indeed use antigens relating to other porcine 
pathogens.  
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